Loutit Brings Significant Experience in Pulmonary and Infectious Disease
SAN DIEGO, Sept. 17 /PRNewswire/ -- Mpex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing products to overcome issues of antibiotic resistance, today announced the appointment of Dr. Jeffery Loutit as the Company's Chief Medical Officer. Dr. Loutit joins Mpex from InterMune, Inc. where since 2001 he has held positions of increasing responsibility and most recently was Vice President of Clinical Science. At InterMune he led multiple Phase 1-3 clinical trials, including two global Phase 3 trials for pirfenidone in patients with idiopathic pulmonary fibrosis. In addition, he negotiated pivotal trial designs for pirfenidone with US and European regulatory agencies and led the late stage clinical development of the anti-infective compound oritavancin, which was subsequently successfully out-licensed.
Prior to entering industry, Dr. Loutit was Chief of the Infectious Diseases Section, Veterans Administration Health Care System in Palo Alto and Assistant Professor of Medicine, Stanford University Medical School, where he published extensively in the area of infectious disease. He received his medical and microbiology degrees from Otago University in New Zealand and is board certified in the US in both infectious disease and internal medicine.
"We believe Jeff will be a great addition to our senior management,"
said Daniel Burgess, President & CEO of Mpex Pharmaceuticals. "His
distinguished reputation and extensive early and late-stage trial
experience will be a perfect complement to our scientific and clinical team
as we advance our drug candidates. In particular, his protocol design
background in both pulmonary and infectious disease medicine is ideally
suited to leading our development efforts for MP-376, an agent being
developed for the treatment of chronic respiratory infections in patie
|SOURCE Mpex Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved